

Chapter 18

REFERENCES

1. Rubin RH, Ikonen T, Gummert JF, et al. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. *Transpl Infect Dis*. 1999;1:29-39.
2. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. *Antimicrob Agents Chemother*. 1993;37:619-624.
3. Rubin RH. Preemptive therapy in immunocompromised hosts [editorial; comment]. *N Engl J Med*. 1991;324:1057-1059.
4. Matsushima A, Tasaki O, Shimizu K, et al. Preemptive antibiotic treatment based on gram staining reduced the incidence of ARDS in mechanically ventilated patients. *J Trauma Injury Infect Crit Care*. 2008;65:309-315; discussion 315.
5. Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. *Infect Dis Clin North Am*. 2009;23:983-996.
6. Bolon MK. The newer fluoroquinolones. *Infect Dis Clin North Am*. 2009;23:1027-1051.
7. Nailor MD, Sobel JD. Antibiotics for Gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. *Infect Dis Clin North Am*. 2009;23:965-982.
8. Zuckerman M, Qamar F, Bono BR. Macrolides, ketolides, and glycylicyclines: azithromycin, clarithromycin, telithromycin, tigecycline. *Infect Dis Clin North Am*. 2009;23:997-1026.
9. Mandell GL, Bennett JE, Dolin R. *Principles and Practice of Infectious Diseases*. 7th ed. Philadelphia, PA: Elsevier; 2010.
10. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians [see comments]. *JAMA*. 1997;278:901-904.
11. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States [see comments] [published erratum appears in *JAMA* 1998;279(6):434]. *JAMA*. 1995;273:214-219.
12. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*. 2009;136:1237-1248.
13. Lorian V. *Antibiotics in Laboratory Medicine*. Baltimore, MD, NY: Williams & Wilkins; 1996.
14. Gibaldi M, Perrier D. *Pharmacokinetics*. 2nd ed. New York, NY: Marcel Dekker; 1982.
15. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. *Infect Dis Clin North Am*. 2009;23:791-815.
16. Van Bambeke F, Barcia-Macay M, Lemaire S, et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. *Curr Opin Drug Disc Develop*. 2006;9:218-230.
17. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis*. 1998;26:1-10.
18. Miranda J, Tunkel AR. Strategies and new developments in the management of bacterial meningitis. *Infect Dis Clin North Am*. 2009;23:925-943.
19. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. *Infect Dis Clin North Am*. 1999;13:595-618.
20. Verklin RM Jr, Mandell GL. Alteration of effectiveness of antibiotics by anaerobiosis. *J Lab Clin Med*. 1977;89:65-71.
21. Edson RS, Terrell CL. The aminoglycosides. *Mayo Clin Proc*. 1999;74:519-528.
22. Craig WA, Kunin CM. Significance of serum protein and tissue binding of antimicrobial agents. *Annu Rev Med*. 1976;27:287-300.
23. Dickinson GM, Bisno AL. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices [see comments]. *Antimicrob Agents Chemother*. 1989;33:597-601.
24. Wilson DA, Rolinson GN. The recovery period following exposure of bacteria to penicillins. *Chemotherapy*. 1979;25:14-22.
25. Novelli A, Fallani S, Cassetta MI, et al. Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains. *Antimicrob Agents Chemother*. 2000;44:3174-3176.
26. McDonald PJ, Wetherall BL, Pruul WB. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. *Rev Infect Dis*. 1981;3:38-44.
27. Chua KB, Howden P. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. *Curr Opin Infect Dis*. 2009;22:525-534.
28. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. *Crit Care Med*. 2009;37:2071-2078.
29. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. *Clin Pharmacokinet*. 1998;35:391-402.
30. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. *Crit Care*. 2008;12(Suppl 4):S2.

31. Fuursted K. Comparative killing activity and postantibiotic effect of streptomycin combined with ampicillin, ciprofloxacin, imipenem, piperacillin or vancomycin against strains of *Streptococcus faecalis* and *Streptococcus faecium*. *Chemotherapy*. 1988;24:229-234.
32. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. *Clin Infect Dis*. 1998;27:23-27.
33. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. *Infect Dis Clin North Am*. 2003;17:503-528.
34. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. *J Antimicrob Chemother*. 1997;39:677-686.
35. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). *Diagn Microbiol Infect Dis*. 1997;28:211-219.
36. Jacoby GA, Munoz-Price LS. The new beta-lactamases. *N Engl J Med*. 2005;352:380-391.
37. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. *Am J Med*. 1997;103:51-59.
38. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. *N Engl J Med*. 1996;335:1445-1453.
39. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clin Infect Dis*. 2001;32:1085-1089.
40. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. *J Hosp Infect*. 2009;73:345-354.
41. Bush KG, Jacoby A. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother*. 2010;54:969-976.
42. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. *Ann Intern Med*. 1991;115:585-590.
43. Lee NLS, Yuen KY, Kumana CR. Beta-lactam antibiotic and beta-lactamase inhibitor combinations. *JAMA*. 2001;285:386-388.
44. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms and clinical management. *Infect Dis Clin North Am*. 2000;14:293-319.
45. Cunha BA. Antibiotic resistance. *Med Clin North Am*. 2000;84:1407-1429.
46. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in *Enterococcus faecium*. *N Engl J Med*. 1988;319:157-161.
47. Noble W, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS Microbiol Lett*. 1992;72:195-198.
48. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect*. 2006;12:16-23.
49. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in *Staphylococcus aureus*. Glycopeptide-Intermediate *Staphylococcus aureus* Working Group. *N Engl J Med*. 1999;340:493-501.
50. Wong SS, Ho PL, Woo PC, et al. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. *Clin Infect Dis*. 1999;29:760-767.
51. Moellering RC Jr. Editorial response: staphylococci vs. glycopeptides—how much are the battle lines changing? *Clin Infect Dis*. 1999;29:768-770.
52. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. *Clin Infect Dis*. 1999;29:245-252.
53. Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins [see comments]. *Ann Intern Med*. 1993;119:353-358.
54. Brun-Buisson C, Legrand P, Philippon A, et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant *Klebsiella pneumoniae*. *Lancet*. 1987;8554:302-306.
55. Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among *Streptococcus pneumoniae*: implications for therapy. *Semin Resp Crit Care Med*. 2005;26:575-616.
56. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. *Mayo Clin Proc*. 2006;81:529-536.
57. Fey PD, Safraneck TJ, Rupp ME, et al. Ceftriaxone-resistant *Salmonella* infection acquired by a child from cattle. *N Engl J Med*. 2000;342:1242-1249.
58. Mølbak K, Baggesen DL, Aarestrup FM, et al. An outbreak of multidrug-resistant, quinolone-resistant *Salmonella enterica* serotype typhimurium DT104. *N Engl J Med*. 1999;341:1420-1425.
59. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. *Clin Infect Dis*. 1998;27:23-27.
60. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. *J Antimicrob Chemother*. 2006;58:916-929.
61. Burroughs SF, Johnson GJ. Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. *Blood*. 1990;75:1473-1480.
62. Davey PG. Pharmacokinetics in liver disease. *J Antimicrob Chemother*. 1988;21(1):1-5.
63. Singh N, Yu VL, Miele LA, et al. Beta-lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease [see comments]. *Am J Med*. 1993;94:251-256.
64. Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. *Rev Infect Dis*. 1985;7:287-313.
65. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control*. 2008;36:309-332.
66. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol*. 2008;29:996-1011.
67. NNIS System of the Centers for Disease Control and Infection. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control*. 2004;32:470-485.
68. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. *Clin Chest Med*. 1999;20:303-316.
69. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. *Arch Intern Med*. 1995;155:1177-1184.

70. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System. *Am J Cardiol*. 1998;82:789-793.
71. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System [see comments]. *Crit Care Med*. 1999;27:887-892.
72. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. *Pediatrics*. 1999;103(4):e9.
73. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. *Eur J Clin Microbiol Infect Dis*. 1996;15:281-285.
74. Luna CM, Boyeras Navarro ID, Luna CM, et al. Management of methicillin-resistant *Staphylococcus aureus* pneumonia. *Curr Opin Infect Dis*. 2010;23:178-184.
75. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant *Staphylococcus aureus* in the genomics era. *J Clin Invest*. 2009;119:2464-2474.
76. Rehm SJ, Tice A. *Staphylococcus aureus*: methicillin-susceptible *S. aureus* to methicillin-resistant *S. aureus* and vancomycin-resistant *S. aureus*. *Clin Infect Dis*. 2010;51(Suppl 2):S176-S182.
77. Yokoe DS, Mermel LA, Anderson DJ, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. *Infect Control Hosp Epidemiol*. 2008;29(Suppl 1):S12-S21.
78. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. *JAMA*. 2010;304:641-648.
79. Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant *Staphylococcus aureus* central line-associated bloodstream infections in US intensive care units, 1997-2007. *JAMA*. 2009;301:727-736.
80. Perencevich EN, Diekema DJ. Decline in invasive MRSA infection: Where to go from here? *JAMA*. 2010;304:687-689.
81. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52:285-292.
82. Neuner EA, Ritchie DJ, Micek ST. New antibiotics for healthcare-associated pneumonia. *Semin Respir Crit Care Med*. 2009;30:92-101.
83. Nordmann P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect Dis*. 2009;9:228-236.
84. Kallen AJ, Hidron AI, Patel JP, et al. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. *Infect Control Hosp Epidemiol*. 2010;31:528-531.
85. Institute for Healthcare Improvement. Central Line Catheter-Related Bloodstream Infection (CR-BSI) Rate per 1,000 Central-Line Days. 2009.
86. Teplick R. Caveats for comparing catheter-associated bloodstream infection rates. *Crit Care Med*. 2011;39:392-394.
87. National Healthcare Safety Network. *First State-Specific Healthcare-Associated Infections Summary Data Report*. 2010. http://www.cdc.gov/hai/pdfs/stateplans/SIR_05_25_2010.pdf.
88. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;49:1-45.
89. Centers for Disease Control and Prevention, National Healthcare Safety Network. *Central Line-Associated Bloodstream Infection (CLABSI) Event*. 2010. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABSCurrent.pdf.
90. Norberg A, Christopher NC, Ramundo ML, et al. Contamination rates of blood cultures obtained by dedicated phlebotomy vs intravenous catheter. *JAMA*. 2003;289:726-729.
91. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. *N Engl J Med*. 1999;340:1-8.
92. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment of candidiasis. *Clin Infect Dis*. 2004;38:161-189.
93. Rubin RH. Surgical wound infection: epidemiology, pathogenesis, diagnosis and management. *BMC Infect Dis*. 2006;6:171.
94. Cardo DM, Falk PS, Mayhall CG. Validation of surgical wound classification in the operating room. *Infect Control Hosp Epidemiol*. 1993;14:255-259.
95. Howe CW. Bacterial flora of clean wounds and its relation to subsequent sepsis. *Am J Surg*. 1964;107:696-700.
96. Garey KW, Lai D, Dao-Tran TK, et al. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. *Antimicrob Agents Chemother*. 2008;52:446-451.
97. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. *Ann Thorac Surg*. 2007;83:1569-1576.
98. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. *N Engl J Med*. 1992;326:281-286.
99. Edwards FH, Engelman RM, Houck P, et al. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery, part I: duration. *Ann Thorac Surg*. 2006;81:397-404.
100. Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical infection. *J Antimicrob Chemother*. 2006;58:645-650.
101. van Kasteren ME, Manniën J, Ott A, et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. *Clin Infect Dis*. 2007;44:921-927.
102. Steinberg JP, Braun BI, Hellinger WC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. *Ann Surg*. 2009;250:10-16.
103. Hawn MT, Itani KM, Gray SH, et al. Association of timely administration of prophylactic antibiotics for major surgical procedures and surgical site infection. *J Am Coll Surg*. 2008;206:814-819.
104. Stulberg JJ, Delaney CP, Neuhauser DV, et al. Adherence to surgical care improvement project measures and the association with postoperative infections. *JAMA*. 2010;303:2479-2485.
105. Hawn MT. Surgical care improvement: should performance measures have performance measures. *JAMA*. 2010;303:2527-2528.
106. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. *Surgery*. 1961;50:161-168.
107. Kurz A, Sessler DI, Lenhardt R, et al. Perioperative normothermia to reduce the incidence of surgical-wound infection

- and shorten hospitalization. Study of Wound Infection and Temperature Group. *N Engl J Med.* 1996;334:1209-1215.
108. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. *Ann Thorac Surg.* 1999;67:352-360.
 109. Haley RW, Culver DH, Morgan WM, et al. Identifying patients at high risk of surgical wound infection: a simple multivariate index of patient susceptibility and wound contamination. *Am J Epidemiol.* 1985;121:206-215.
 110. Culver DH, Horan TC, Gaynes RP, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. *Am J Med.* 1991;91:S152-S157.
 111. Kirby JP, Mazuski JE. Prevention of surgical site infection. *Surg Clin North Am.* 2009;89:365-389, viii.
 112. Lipsett PA. Surgical critical care: fungal infections in surgical patients. *Crit Care Med.* 2006;34(9 Suppl):S215-S224.
 113. Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. *Crit Care Med.* 2006;34:1216-1224.
 114. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis.* 2010;50:133-164.
 115. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation.* 2008;118:887-896.
 116. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation.* 2007;116:1736-1754.
 117. Cheng TO. Endocarditis prophylaxis in patients with mitral valve prolapse remains a controversial issue despite the new American Heart Association guidelines. *Int J Cardiol.* 2008;127:149-150.
 118. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171:388-416.
 119. Ewig S, Welte T, Chastre J, et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. *Lancet Infect Dis.* 2010;10:279-287.
 120. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. *Curr Opin Infect Dis.* 2009;22:316-325.
 121. Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. *Clin Infect Dis.* 2010;51:S12-S17.
 122. Johnstone J, Majumdar SR, Fox JD, et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. *Chest.* 2008;134:1141-1148.
 123. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44:S27-S72.
 124. Wip C, Napolitano L. Bundles to prevent ventilator-associated pneumonia: how valuable are they? *Curr Opin Infect Dis.* 2009;22:159-166.
 125. Zilberberg MD, Shorr AF, Kollef MH. Implementing quality improvements in the intensive care unit: ventilator bundle as an example. *Crit Care Med.* 2009;37:305-309.
 126. Niederman MS. Fighting vampires and ventilator-associated pneumonia: is silver the magic bullet? *Chest.* 2010;137:1007-1009.
 127. Bonten MJ, Chastre J, Craig WA, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Resp Crit Care Med.* 2005;171(4):388-416.
 128. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of *Klebsiella* bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. *Antimicrob Agents Chemother.* 1992;36:2639-2644.
 129. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. *Am J Med.* 2002;113(Suppl 1A):14S-19S.
 130. Hooton TM, Bradley F, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines From the Infectious Diseases Society of America. *Clin Infect Dis.* 2010;50:625-663.
 131. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med.* 2010;362:1804-1813.
 132. Wagenlehner FM, Weidner W, Naber KG. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. *Clin Pharmacokinet.* 2007;46:291-305.
 133. Stanley JD, Burns RP. Clostridium difficile and the surgeon. *Am Surg.* 2010;76:235-244.
 134. Bauer MP, van Dissel JT, Kuijper EJ. Clostridium difficile: controversies and approaches to management. *Curr Opin Infect Dis.* 2009;22:517-524.
 135. Bhattacharya M, Parakh A, Narang M. Tigecycline. *J Postgrad Med.* 2009;55:65-68.
 136. Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. *J Hepatobiliary Pancreat Surg.* 2007;14:59-67.
 137. Byrnes MC, Mazuski JE. Antimicrobial therapy for acute colonic diverticulitis. *Surg Infect.* 2009;10:143-154.
 138. Jacobs DO. Clinical practice. Diverticulitis. *N Engl J Med.* 2007;357:2057-2066.
 139. Hansson J, Körner U, Khorram-Manesh A, et al. Randomized clinical trial of antibiotic therapy versus appendectomy as primary treatment of acute appendicitis in unselected patients. *Br J Surg.* 2009;96:473-481.
 140. Isenmann R, Rau B, Beger HG. Bacterial infection and extent of necrosis are determinants of organ failure in patients with acute necrotizing pancreatitis. *Br J Surg.* 1999;86:1020-1024.
 141. Bakker O, van Santvoort H, Besselink M, et al. Prevention, detection, and management of infected necrosis in severe acute pancreatitis. *Curr Gastroenterol Rep.* 2009;11:104-110.

142. Jafri NS, Mahid SS, Idstein SR, et al. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis. *Am J Surg*. 2009;197:806-813.
143. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *Am J Gastroenterol*. 2006;101:2379-2400.
144. Carael M, Schwartlander B, Piot P. Epidemiology of HIV infection. In: Armstrong D, Cohen J, eds. *Infectious Diseases*. Philadelphia, PA: Mosby-Year Book; 1999.
145. Gottlieb MS, Schroff R, Schanker HM, et al. *Pneumocystis carinii* pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. *N Engl J Med*. 1981;305:1425-1431.
146. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired *Pneumocystis carinii* pneumonia: initial manifestation of cellular immune dysfunction. *N Engl J Med*. 1981;305:1431-1438.
147. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. *MMWR Recomm Rep*. 2008;57:1-12.
148. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. *N Engl J Med*. 1998;339:33-39.
149. Rizzardì GP, Pantaleo G. The immunopathogenesis of HIV-1 infection. In: Armstrong D, Cohen J, eds. *Infectious Diseases*. Philadelphia, PA: Mosby-Year Book; 1999.
150. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. *Antimicrob Agents Chemother*. 1993;37(6):1207-1213.
151. Vella S, Florida M. Antiviral therapy. In: Armstrong D, Cohen J, eds. *Infectious Diseases*. Philadelphia, PA: Mosby-Year Book; 1999.
152. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society—USA panel. *JAMA*. 2010;304:321-333.
153. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. 1996;272:1167-1170.
154. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. *N Engl J Med*. 1996;334:426-431.
155. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society—USA Panel. *J Am Med Assoc*. 1998;280:78-86.
156. Rubin RH. *Clinical Approach to Infection in the Compromised Host*. 4th ed. New York, NY: Kluwer/Academic Press; 2003.
157. Jarvis WR. Epidemiology of nosocomial fungal infection, with emphasis on *Candida* species. *Clin Infect Dis*. 1995;20:1526-1530.
158. Pfaller MA. Epidemiology of candidiasis. *J Hosp Infect*. 1995;20(Suppl):329-338.
159. Hopkins CC, Weber DH, Rubin RH. Invasive aspergillus infection: possible non-ward common source within the hospital environment. *J Hosp Infect*. 1989;13:19-25.
160. Paya CV. Fungal infections in solid-organ transplantation. *Clin Infect Dis*. 1993;16:677-688.
161. Rubin RH, Ikonent GJ, Morris R. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. *Transplant Infect Dis*. 1999;1:29-39.
162. Edwards JE Jr, Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. *Clin Infect Dis*. 1997;25:43-59.
163. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2008;46:1801-1812.
164. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2007;45:807-825.
165. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. *Clin Infect Dis*. 2005;41:1217-1223.
166. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50:291-322.
167. Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2007;45:1255-1265.
168. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality [see comments]. *Clin Infect Dis*. 1992;15:414-421.
169. Denning DW. Invasive aspergillosis. *Clin Infect Dis*. 1998;26:781-803.
170. Boutati EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center at a cancer center and implications for management. *Blood*. 1997;90:999-1008.
171. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. *Am J Med*. 1987;83:236-242.
172. White MH. Antifungal agents. In: Armstrong D, Cohen J, eds. *Infectious Disease*. Philadelphia, PA: Mosby; 1999.
173. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of *Candida* species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J Clin Microbiol*. 2010;48:1366-1377.
174. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. *Drugs*. 2007;67:269-298.
175. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med*. 2002;347:408-415.
176. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. *Ann Pharmacother*. 2008;42:1429-1438.
177. Deresinski SC, Stevens DA. Caspofungin. *Clin Infect Dis*. 2003;36:1445-1457.
178. Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. *J Antimicrob Chemother*. 2010;65:1108-1018.
179. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis*. 2004;39:797-802.
180. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. *Lancet Infect Dis*. 2005;5:775-785.

181. Romaschin AD, Harris DM, Ribeiro MB, et al. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. *J Immunol Methods*. 1998;212:169-185.
182. Carlet J. Rapid diagnostic methods in the detection of sepsis. *Infect Dis Clin North Am*. 1999;13:483-494.
183. Arnalich F, Garcia-Palomero E, López J, et al. Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. *Infect Immun*. 2000;68:1942-1945.
184. Böhrer H, Qiu F, Zimmermann T, et al. Role of NFkappaB in the mortality of sepsis. *J Clin Invest*. 1997;100:972-985.
185. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. *Clin Infect Dis*. 2006;42:1417-1427.
186. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. *J Clin Microbiol*. 1995;33:24-27.
187. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. *J Clin Microbiol*. 1997;35:1353-1360.
188. Flahaut M, Sanglard D, Monod M, et al. Rapid detection of *Candida albicans* in clinical samples by DNA amplification of common regions from *C. albicans*-secreted aspartic proteinase genes. *J Clin Microbiol*. 1998;36:395-401.
189. Kane TD, Alexander JW, Johannigman JA. The detection of microbial DNA in the blood: a sensitive method for diagnosing bacteremia and/or bacterial translocation in surgical patients. *Ann Surg*. 1998;227:1-9.
190. Warwick S, Wilks M, Hennessy E, et al. Use of quantitative 16S ribosomal DNA detection for diagnosis of central vascular catheter-associated bacterial infection. *J Clin Microbiol*. 2004;42:1402-1408.
191. NNIS Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System Report, Data, Summary from October 1986-April 1998, Issued June 1998. Atlanta, GA: Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services; 1998:1-25.
192. Amsden GW. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*. 6th ed. Philadelphia, PA: Elsevier; 2005:634-700.
193. Raymond DP, Kuehnert MJ, Sawyer RG. Preventing antimicrobial-resistant bacterial infections in surgical patients. *Surg Infect (Larchmt)*. 2002;3:375-385.
194. Jones Rd N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *Clin Infect Dis*. 2010;51:S81-S87.